Partially hydrolysed guar gum (PHGG) appeared to be efficacious in patients with irritable bowel syndrome-associated chronic constipation.
An accelerated treatment algorithm appeared to benefit patients with large pancreatic WON in terms of length-of-stay in the hospital and major complications.
A 66-year-old patient enters the ER with persistent fever, night sweats and significant weight loss. He is admitted with the diagnosis of “persistent bronchopneumonia”...
A study found faecal microbiota transplantation was safe and non-inferior to vancomycin in patients with primary Clostridioides difficile infections.
Etrasimod was associated with favourable outcomes and tolerability in patients with moderately to severely active CD in a phase 2 trial extension.
Key issues were discussed at the UEG Week related to current approaches to diagnostics, treatment and practical takeaways of malabsorption syndromes.
A special congres session took a critical look at common errors in the management of lower gastrointestinal conditions, providing insights for clinical practice.
Hepatobiliary and disease guidelines and updates were discussed during a session on prancreas-related cancer, exocrine insufficiency, cysts, and NASH.
A meta-analysis showed that HS familial cases are associated with higher cardiovascular diseases, hyperlipidaemia, and diabetes mellitus risk.
Post-hoc analysis of the THRIVE-AA1 and THRIVE-AA2 trials showed satisfaction in the THRIVE-AA1 and THRIVE-AA2 trials as early as week 12.
Povorcitinib led to a sustained reduction of pruritus and skin lesions in prurigo nodularis in a randomised-controlled phase 2 study.
Continuing bimekizumab for 2 years led to maintenance of various HiSCR and International Hidradenitis Suppurativa Severity Score System (IHS4) scores.
Orismilast demonstrated higher rates of Investigator Global Assessment of 0/1 at week 16 compared with placebo in the phase 2b ADESOS trial.
A comparison of topical delgocitinib with systemic alitretinoin for treating patients with chronic hand eczema (CHE) favoured the pan-JAK inhibitor.
A comprehensive analysis from the German Psoriasis Registry (PsoBest) highlights the evolution of systemic drug use for psoriasis over the past 15 years.
Delgocitinib was associated with a reduction in interferon gamma (IFN-γ), chemokine ligand (CXCL)9, and CXCL10 in the treatment of FFA.
A study including data from over 30,000 participants revealed that early onset of atopic dermatitis (AD) leads to a psychosocial burden throughout adult life.
Withdrawing nemolizumab led to an 8-fold increase in the likelihood of a prurigo nodularis (PN) relapse compared with uninterrupted therapy.
A single dose of 750 mg imsidolimab yielded a GPPPGA score of clear or almost clear in over half of the participants with GPP after 4 weeks.
A combination of eye-tracking tests could help to speed up the diagnostic process and make it more efficient, according to the authors.